RhumbLine Advisers
UNCY icon

RhumbLine Advisers’s Unicycive Therapeutics UNCY Stock Holding History

RhumbLine Advisers’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137K Buy
+29,288
New +$216K ﹤0.01% 3419

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

RhumbLine Advisers's UNCY Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 29,288 shares worth $137K. The stake represents ﹤0.01% of the portfolio and ranks #3419 among its holdings.

28 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • RhumbLine Advisers held 29,288 shares of Unicycive Therapeutics worth $137K as of Q2 2026.
  • Unicycive Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3419 holding.
  • 28 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.